Pharmacokinetics and safety of the novel amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist YM90K in healthy men.

Abstract

YM90K is a novel, selective and competitive alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist with neuroprotective properties, and it is currently under development for the intravenous treatment of stroke and other conditions of acute neuronal degeneration. The safety and pharmacokinetics of YM90K in healthy men was investigated after single doses up to 36 mg and repeated doses of 24 mg given by intravenous infusion over 3 hours. YM90K was well tolerated in healthy men and induced only mild changes in kidney function markers. Unchanged plasma drug concentration reached a near steady state during 3-hour infusion and rapidly decreased in a biphasic manner after the completion of infusion. YM90K showed linear pharmacokinetics. In the repeated-dose study, no significant differences were observed in pharmacokinetics of YM90K between the first and fifth dose. Unchanged urinary drug excretion was as high as 63.2% to 78.3% of the dose, most of which was excreted within 1 hour after the completion of infusion. YM90K is thought to be excreted mainly by renal tubular secretion. YM90K showed neither significant adverse reactions nor severe abnormalities in physical and laboratory examinations of the study participants and demonstrated safety and pharmacokinetic profiles compatible with clinical use.

• Authors: K Umemura, K Kondo, Y Ikeda, Y Teraya, H Yoshida, M Homma, T Uematsu, M Nakashima
• Journal: Journal of clinical pharmacology (J Clin Pharmacol) Vol. 37 Issue 8 Pg. 719-27 (Aug 1997) ISSN: 0091-2700 [Print] England
• PMID: 9378844 (Publication Type: Clinical Trial, Clinical Trial, Phase I, Controlled Clinical Trial, Journal Article)

Chemical References

• Neuroprotective Agents
• Quinoxalines
• Receptors, AMPA
• 6-(1H-imidazol-1-yl)-7-nitro-2,3(1H,4H)-quinoxalinedione

Topics

• Adult
• Area Under Curve
• Chromatography, High Pressure Liquid
• Half-Life
• Humans
• Infusions, Intravenous
• Male
• Neuroprotective Agents (administration & dosage, adverse effects, pharmacokinetics)
• Quinoxalines (administration & dosage, adverse effects, pharmacokinetics)
• Receptors, AMPA (antagonists & inhibitors)
• Spectrophotometry, Ultraviolet